Journal article

New developments and directions in the clinical application of the echinocandins

CC Chang, MA Slavin, SCA Chen

Archives of Toxicology | SPRINGER HEIDELBERG | Published : 2017

Abstract

The echinocandins—caspofungin, anidulafungin and micafungin—are semi-synthetic cyclic hexapeptide antimicrobial agents with modified N-linked acyl lipid side chains which anchor the compounds to the phospholipid bilayer of the fungal cell membrane, thereby inhibiting synthesis of fungal cell wall glucan. Over the last 10 years, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC). Echinocandins are generally well tolerated, but their use is limited by their requirement for daily intravenous dosing, lack of oral formulation and limited spectrum. In critically ill patients, it is also recognised that achievement of their phar..

View full abstract

University of Melbourne Researchers